$LLY

AI 分析

生成於 May 11, 2026

AI Score
74/ 100
Hold$LLY

Eli Lilly and Company

$LLYNYSEHealthcareMega-Cap

Eli Lilly discovers, develops, and markets pharmaceutical products, with leading positions in diabetes (Mounjaro), obesity (Zepbound), and oncology.

Market Cap
$720.0B
Revenue (TTM)
$41.3B
+32.0%
Net Income (TTM)
$9.4B
+68.0%
EPS (TTM)
$10.35
P/E Ratio
72.0
Dividend Yield
0.7%
52-Week Range
$600-$972
Beta
0.42
Dimension Scores
Fundamental
72
Technical
62
Sentiment
78
Risk / Reward
60
Momentum
82
FundTechSentRiskMome
Financial Health
Profitability
77strong
Growth
85strong
Liquidity
68strong
Solvency
74strong
Efficiency
70strong

Valuation, technical analysis, investment thesis, risk assessment and more for $LLY

Free · No credit card required

免責聲明: AI 生成的分析僅供教育參考,不構成投資建議。請始終諮詢合格的理財顧問。

探索更多

用 AI 分析任意股票

獲取涵蓋基本面、技術面、情緒面、風險評估和投資論點的結構化研究報告——約 60 秒完成。